Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Current Liabilities (2020 - 2025)

Apellis Pharmaceuticals has reported Total Current Liabilities over the past 6 years, most recently at $323.6 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $323.6 million for Q4 2025, up 74.44% from a year ago — trailing twelve months through Dec 2025 was $323.6 million (up 74.44% YoY), and the annual figure for FY2025 was $323.6 million, up 74.44%.
  • Total Current Liabilities for Q4 2025 was $323.6 million at Apellis Pharmaceuticals, up from $279.5 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for APLS hit a ceiling of $323.6 million in Q4 2025 and a floor of $83.7 million in Q1 2021.
  • Median Total Current Liabilities over the past 5 years was $172.0 million (2023), compared with a mean of $174.6 million.
  • Biggest five-year swings in Total Current Liabilities: surged 172.09% in 2021 and later dropped 25.08% in 2024.
  • Apellis Pharmaceuticals' Total Current Liabilities stood at $131.8 million in 2021, then increased by 27.12% to $167.6 million in 2022, then surged by 47.72% to $247.6 million in 2023, then dropped by 25.08% to $185.5 million in 2024, then skyrocketed by 74.44% to $323.6 million in 2025.
  • The last three reported values for Total Current Liabilities were $323.6 million (Q4 2025), $279.5 million (Q3 2025), and $200.7 million (Q2 2025) per Business Quant data.